Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer
- 1 June 2019
- journal article
- research article
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (11) , 115027
Abstract
The purpose of this study was the evaluation of the impact of a variable relative biological effectiveness (RBE) compared to a constant RBE value of 1.1 in proton therapy prostate trials due to uncertainties in α / β ratio. Twenty patients receiving passive scattered proton therapy (PSPT) and fifteen patients receiving intensity modulated proton therapy (IMPT) were compared to twenty patients treated with 7-field intensity modulated photon therapy (IMRT). For proton beam therapy (PBT), the RBE was estimated using two different RBE models. Tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP) were assessed. For one of the RBE models, dosimetric indices assuming a low α / β were ~10%–11% larger compared to using a fixed RBE. A different model resulted in 1%–3% lower values independent of α / β . Comparing PBT with IMRT revealed a negligible difference in TCP for a fixed RBE. Applying a variable RBE revealed an increase in TCP by 6% for PBT compared to IMRT for one model but a decrease of 2% for the other. Variable RBE values in PSPT resulted in an increase in NTCP for rectum from 7% to 11% for a fixed RBE with one model but a decrease to 6% for another. For IMPT, NTCP increased from 5% to 9% for a fixed RBE for one model but decreased to 3% using the other. The NTCP for bladder increased for PSPT for both models, from 11% to 19% and 14%, respectively. For IMPT, the NTCP increased from 12% to 17% using one model but decreased to 11% with the other. In radiation therapy for prostate cancer, disregarding variable RBE may lead to either underestimation or overestimation of the expected TCP and NTCP, depending on the RBE model and α / β . This should be considered when estimating uncertainties when comparing PBT and IMRT outcomes in clinical trials.Keywords
Funding Information
- National Cancer Institute (U19 CA-21239)
This publication has 50 references indexed in Scilit:
- Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liverPhysics in Medicine & Biology, 2013
- TOPAS: An innovative proton Monte Carlo platform for research and clinical applicationsMedical Physics, 2012
- Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patientsActa Oncologica, 2012
- Multi-Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer Focusing on the Incidence of Late Rectal ToxicitiesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Factors Predictive of Tumor Recurrence and Survival After Initial Complete Response of Esophageal Squamous Cell Carcinoma to Definitive ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Modeling of α/β for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancerJournal of Experimental & Clinical Cancer Research, 2009
- A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent ImplantInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Combined Use of Monte Carlo DNA Damage Simulations and Deterministic Repair Models to Examine Putative Mechanisms of Cell KillingRadiation Research, 2008
- Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical controlRadiotherapy and Oncology, 2007
- Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 GyJournal of Clinical Oncology, 2006